Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...

After flexing its antibody-drug conjugate (ADC) bona fides at ASCO last year, AbbVie is advancing its solid tumor ambitions ...

This marks the first and only FDA-approved medicine for low-grade serous ovarian cancer (LGSOC) that tests positive for a gene change known as the KRAS mutation. The treatment includes two drugs ...

Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million ...

Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ...